Clinical Trial Update: A Worldwide Pregnancy Safety Study to Assess Maternal, Fetal, and Infant Outcomes Following Exposure to Efgartigimod During Pregnancy and/or Breastfeeding.

View source ↗

Summary

A worldwide pregnancy safety study is recruiting to assess maternal, fetal, and infant outcomes after exposure to efgartigimod during pregnancy and/or breastfee…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Inflammatory Demyelinating Polyneuropathy
• Myasthenia Gravis

Drugs mentioned

• VYVGART (EFGARTIGIMOD ALFA)

Snippet

Sponsor: argenx | Conditions: Myasthenia Gravis, CIDP - Chronic Inflammatory Demyelinating Polyneuropathy | Status: RECRUITING